Overview

International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Pleuropulmonary Blastoma (PPB) is very rare and there is no established "standard" or "best" therapy. For many years, children with PPB around the world have been treated according to decisions made case-by-case in many different hospitals by many different physicians. No treatment has been tested in a large group of PPB patients. The goal is to treat many children with one treatment program and to learn the results of the treatment.
Phase:
N/A
Details
Lead Sponsor:
Children's Hospitals and Clinics of Minnesota
Treatments:
Cyclophosphamide
Dactinomycin
Doxorubicin
Ifosfamide
Isophosphamide mustard
Liposomal doxorubicin
Vincristine